277 related articles for article (PubMed ID: 24845612)
1. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
[TBL] [Abstract][Full Text] [Related]
2. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
[TBL] [Abstract][Full Text] [Related]
3. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
4. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
[TBL] [Abstract][Full Text] [Related]
6. Histone-modifying genes as biomarkers in hepatocellular carcinoma.
Hung SY; Lin HH; Yeh KT; Chang JG
Int J Clin Exp Pathol; 2014; 7(5):2496-507. PubMed ID: 24966962
[TBL] [Abstract][Full Text] [Related]
7. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.
Xie CR; Li Z; Sun HG; Wang FQ; Sun Y; Zhao WX; Zhang S; Zhao WX; Wang XM; Yin ZY
Oncotarget; 2015 Dec; 6(38):40940-52. PubMed ID: 26517514
[TBL] [Abstract][Full Text] [Related]
8. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
11. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.
Feng H; Yu Z; Tian Y; Lee YY; Li MS; Go MY; Cheung YS; Lai PB; Chan AM; To KF; Chan HL; Sung JJ; Cheng AS
J Hepatol; 2015 May; 62(5):1100-11. PubMed ID: 25500144
[TBL] [Abstract][Full Text] [Related]
12. Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification.
Gherardi S; Ripoche D; Mikaelian I; Chanal M; Teinturier R; Goehrig D; Cordier-Bussat M; Zhang CX; Hennino A; Bertolino P
Biochim Biophys Acta Gene Regul Mech; 2017 Apr; 1860(4):427-437. PubMed ID: 28215965
[TBL] [Abstract][Full Text] [Related]
13. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
14. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
[TBL] [Abstract][Full Text] [Related]
15. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
[TBL] [Abstract][Full Text] [Related]
16. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.
He C; Xu J; Zhang J; Xie D; Ye H; Xiao Z; Cai M; Xu K; Zeng Y; Li H; Wang J
Hum Pathol; 2012 Sep; 43(9):1425-35. PubMed ID: 22406368
[TBL] [Abstract][Full Text] [Related]
17. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
[TBL] [Abstract][Full Text] [Related]
18. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic alterations contribute to promoter activity of imprinting gene IGF2.
Zheng QF; Xu B; Wang HM; Ding LH; Liu JY; Zhu LY; Qiu H; Zhang L; Ni GY; Ye J; Gao SB; Jin GH
Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):117-124. PubMed ID: 29413895
[TBL] [Abstract][Full Text] [Related]
20. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]